<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03285438</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC17.0125 RENOVE</org_study_id>
    <nct_id>NCT03285438</nct_id>
  </id_info>
  <brief_title>REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.</brief_title>
  <acronym>RENOVE</acronym>
  <official_title>REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE Open-label, Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Saint-Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk&#xD;
      factors have a high risk of recurrence after stopping anticoagulation. In these patients,&#xD;
      international guidelines recommend indefinite anticoagulation. However, prolonged use of&#xD;
      warfarin or DOAC at therapeutic dose is associated with a significant risk of bleeding.&#xD;
      Consequently, it has been hypothesized that extended anticoagulation at lower dosage might be&#xD;
      as effective as and safer than full dose of anticoagulation. However, low-dose warfarin (INR&#xD;
      1.5-2) was less effective and not safer than conventional dose warfarin (INR 2-3).&#xD;
&#xD;
      Low dose of DOAC has the potential to validate this hypothesis. In a first randomized trial&#xD;
      comparing full-dose or low-dose apixaban with a placebo during an additional one year of&#xD;
      anticoagulation in patients where physicians were uncertain for prolonging anticoagulation&#xD;
      (&quot;Amplify-extension trial&quot;), low-dose apixaban was more effective than placebo without any&#xD;
      major concern regarding safety and possibly as effective as and safer than full-dose&#xD;
      apixaban; in a second randomized trial comparing full-dose or low-dose rivaroxaban with&#xD;
      aspirin, during an additional one year of anticoagulation in patients where physicians were&#xD;
      uncertain for prolonging anticoagulation (&quot;Einstein-Choice trial&quot;), low-dose rivaroxaban was&#xD;
      more effective than aspirin without any major concern regarding safety and possibly as&#xD;
      effective as and safer than full-dose rivaroxaban. However, these two studies were not&#xD;
      designed and powered to demonstrate non-inferiority on efficacy and superiority on safety of&#xD;
      a reduced dose of DOAC versus a full dose DOAC and the selected population did not have&#xD;
      strong indications for indefinite anticoagulation. Thus, there is currently no evidence to&#xD;
      recommend a reduced dose rather than a full dose of DOAC for extended therapy in patients at&#xD;
      high risk of recurrent VTE. Consequently, a randomized trial comparing low-dose DOAC with&#xD;
      full-dose DOAC therapy in patients at high risk of recurrent VTE is needed and justified.&#xD;
&#xD;
      Main hypothesis:&#xD;
&#xD;
      After VTE at high risk of recurrence initially treated during 6 (-15 days) to 24 (+ 3 months)&#xD;
      uninterrupted months, a reduced dose of DOAC will be non-inferior to a full dose of DOAC in&#xD;
      terms of recurrent VTE during extended anticoagulation phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk&#xD;
      factors have a high risk of recurrence after stopping anticoagulation. In the &quot;PADIS-PE&quot;&#xD;
      trial comparing an additional 18 months of warfarin (target international normalized ratio&#xD;
      (INR) from 2 to 3) versus placebo in 371 patients who have completed 6 months of&#xD;
      anticoagulation for a first unprovoked pulmonary embolism, the PADIS-PE trial confirmed that&#xD;
      prolonged warfarin therapy was highly effective for preventing recurrent VTE but that benefit&#xD;
      was lost after stopping anticoagulation. In another trial, similar findings had been reported&#xD;
      using direct oral anticoagulants (DOAC) at therapeutic dose. These results reinforce&#xD;
      international recommendation for indefinite anticoagulation in patients at high risk of&#xD;
      recurrent VTE (unprovoked VTE, recurrent VTE or persistent risk factors).&#xD;
&#xD;
      However, prolonged use of warfarin or DOAC at therapeutic dose is associated with a&#xD;
      significant risk of bleeding. Consequently, it has been hypothesized that extended&#xD;
      anticoagulation at lower dosage might be as effective as and safer than full dose of&#xD;
      anticoagulation. However, low-dose warfarin (INR 1.5-2) was less effective and not safer than&#xD;
      conventional dose warfarin (INR 2-3).&#xD;
&#xD;
      Low dose of DOAC has the potential to validate this hypothesis. First, DOACs have been shown&#xD;
      to be as effective as and safer than warfarin (INR 2-3) during the first 6 months of&#xD;
      anticoagulation after an acute VTE. Second, in a first randomized trial comparing full-dose&#xD;
      or low-dose apixaban with a placebo during an additional one year of anticoagulation in&#xD;
      patients where physicians were uncertain for prolonging anticoagulation (&quot;Amplify-extension&#xD;
      trial&quot;), low-dose apixaban was more effective than placebo without any major concern&#xD;
      regarding safety and possibly as effective as and safer than full-dose apixaban; in a second&#xD;
      randomized trial comparing full-dose or low-dose rivaroxaban with aspirin, during an&#xD;
      additional one year of anticoagulation in patients where physicians were uncertain for&#xD;
      prolonging anticoagulation (&quot;Einstein-Choice trial&quot;), low-dose rivaroxaban was more effective&#xD;
      than aspirin without any major concern regarding safety and possibly as effective as and&#xD;
      safer than full-dose rivaroxaban. However, these two studies were not designed and powered to&#xD;
      demonstrate non-inferiority on efficacy and superiority on safety of a reduced dose of DOAC&#xD;
      versus a full dose DOAC and the selected population did not have strong indications for&#xD;
      indefinite anticoagulation. Thus, there is currently no evidence to recommend a reduced dose&#xD;
      rather than a full dose of DOAC for extended therapy in patients at high risk of recurrent&#xD;
      VTE. Consequently, a randomized trial comparing low-dose DOAC with full-dose DOAC therapy in&#xD;
      patients at high risk of recurrent VTE is needed and justified.&#xD;
&#xD;
      Main hypothesis:&#xD;
&#xD;
      After VTE at high risk of recurrence initially treated during 6 (-15 days) to 24 (+3 months)&#xD;
      uninterrupted months, a reduced dose of DOAC will be non-inferior to a full dose of DOAC in&#xD;
      terms of recurrent VTE during extended anticoagulation phase.&#xD;
&#xD;
      Design&#xD;
&#xD;
      The &quot;RENOVE&quot; trial is designed as an academic, multicenter, open, with blind evaluation&#xD;
      (PROBE), randomized, parallel arm, controlled, trial sponsored by the Brest University&#xD;
      Hospital Center. Patients meeting the inclusion criteria will be randomized at visit 1 (day&#xD;
      0) and allocated to receive:&#xD;
&#xD;
        -  either a reduced dose of DOAC (apixaban 2.5 mg twice daily or rivaroaxaban 10 mg once&#xD;
           daily) during a mean follow-up period of 24 months (12 to 48 months)&#xD;
&#xD;
        -  or a full dose of DOAC (Apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily)&#xD;
           during a mean follow-up period of 24 months (12 to 48 months).&#xD;
&#xD;
      The study is powered to demonstrate the following hypotheses using a three steps hierarchical&#xD;
      analysis:&#xD;
&#xD;
        -  Primary hypothesis: non-inferiority of a reduced dose of DOAC as compared to a full dose&#xD;
           of DOAC on the risk of recurrent VTE;&#xD;
&#xD;
        -  Secondary hypothesis: in case of the confirmation of the previous hypothesis,&#xD;
           superiority of a reduced dose of DOAC on the risk of major or clinically relevant&#xD;
           non-major bleeding.&#xD;
&#xD;
        -  Third hypothesis: in case of the confirmation of the previous hypothesis, superiority of&#xD;
           a reduced dose of DOAC on the risk of the composite of recurrent VTE, major bleeding or&#xD;
           clinically relevant non major bleeding.&#xD;
&#xD;
      Randomization will be centralized and stratified on:&#xD;
&#xD;
        -  Center&#xD;
&#xD;
        -  Type of DOAC&#xD;
&#xD;
        -  antiplatelet agent taking&#xD;
&#xD;
      At visit 1, patients will have a therapeutic education and they will be instructed to call&#xD;
      research team in case of any medical event during the study treatment period. Follow-up&#xD;
      visits will be planned at 3, 6, 12 months and every 6 months until study end (i.e.; after the&#xD;
      last included patient has achieved 12- month of study treatment period).&#xD;
&#xD;
      All critical events will be adjudicated by an independent adjudication committee blinded from&#xD;
      the treatment allocation. A data safety board will be constituted and will meet on a regular&#xD;
      basis. Duration of each patient's participation will be on average 24 months (12 months for&#xD;
      the last included patient) and a total duration of the study is expected for 48 months.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Main Objective&#xD;
&#xD;
           • To demonstrate that a reduced dose of DOAC is non-inferior to a full dose of DOAC for&#xD;
           the risk of recurrent VTE during the during a mean study treatment period of 24 months&#xD;
           in patients with VTE that warrants indefinite anticoagulation and who have been&#xD;
           initially treated for 6 (-15 days) to 24 (+3 months) uninterrupted months.&#xD;
&#xD;
        -  Secondary Objectives&#xD;
&#xD;
           • Key secondary objectives: if the main objective is verified, key secondary objectives&#xD;
           are to demonstrate the superiority of a reduced dose of DOAC over a full dose of DOAC&#xD;
           during a mean study treatment period of 24 months :&#xD;
&#xD;
        -  on the risk of major or CRNMB and, if confirmed,&#xD;
&#xD;
        -  on the composite of recurrent VTE, major bleeding or CRNMB.&#xD;
&#xD;
           • Other secondary objectives:&#xD;
&#xD;
        -  To evaluate the benefit of a reduced dose of DOAC on the risk of major bleeding during a&#xD;
           mean study treatment period of 24 months&#xD;
&#xD;
        -  To evaluate the benefit of a reduced dose of DOAC on the composite outcome of recurrent&#xD;
           VTE and major bleeding during a mean study treatment period of 24 months&#xD;
&#xD;
        -  To determine the impact of a reduced dose of DOAC on deaths of all causes and deaths&#xD;
           related to recurrent VTE or major bleeding during a mean study treatment period of 24&#xD;
           months&#xD;
&#xD;
        -  To evaluate dyspnea and post-thrombotic syndrome (villalta score)(65).&#xD;
&#xD;
        -  To evaluate compliance treatment using the Morisky auto-questionnaire (66,67)&#xD;
&#xD;
        -  To analyse the treatment effect on recurrent VTE and major bleeding and CRNM among&#xD;
           predefined sub-groups (screening for heterogeneity among predefined strata).&#xD;
&#xD;
      Sample size justification&#xD;
&#xD;
      In this three steps hierarchical trial, the sample size was calculated on the basis of the&#xD;
      following three conditional hypotheses:&#xD;
&#xD;
        -  Primary hypothesis: non inferiority of a reduced dose of DOAC compared to a full dose of&#xD;
           DOAC on the risk of recurrent VTE. Based on an expected rate of recurrent VTE of 2%/year&#xD;
           (4% during the entire study period (i.e.; mean study treatment period of 24 months)) in&#xD;
           each group and a requirement that the study would have 90% power to exclude a hazard&#xD;
           ratio of 1.7* for the primary outcome with a reduced dose of DOAC, at a two-sided alpha&#xD;
           level of 0.05, 1030 patients need to be included in each treatment group.&#xD;
&#xD;
        -  Secondary hypothesis: in case of the confirmation of the previous hypothesis,&#xD;
           superiority of a reduced dose of DOAC on the risk of major or clinically relevant non&#xD;
           major bleeding. Assuming an estimated incidence in the full-dose DOAC group of 10% in&#xD;
           the entire study period and a reduction in the relative risk of at least 35%** with a&#xD;
           reduced dose of DOAC as compared with a full dose of DOAC, 966 patients in each group&#xD;
           for the study would have 80% power to show the superiority of a reduced dose of DOAC&#xD;
           over warfarin, at a two-sided alpha level of 0.05.&#xD;
&#xD;
        -  Third hypothesis: in case of the confirmation of the previous hypothesis, superiority of&#xD;
           a reduced dose of DOAC on the risk of the composite of recurrent VTE, major bleeding or&#xD;
           clinically relevant non major bleeding. Assuming an estimated incidence in the full-dose&#xD;
           DOAC group of 14% and 10% in the reduced-dose DOAC group in the entire study period,&#xD;
           1029 patients in each group for the study would have 80% power to show the superiority&#xD;
           of a reduced dose over a full dose of DOAC, at a two-sided alpha level of 0.05.&#xD;
&#xD;
      Taking in account 5% of loss of follow-up, a total of 2200 patients are required in order to&#xD;
      be able to confirm these three conditional hypotheses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">November 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The trial is designed as an academic, multicenter, open, with blind evaluation (PROBE), randomized, parallel arm, controlled.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent VTE</measure>
    <time_frame>during a mean study treatment period of 24 months</time_frame>
    <description>Adjudicated symptomatic objectively confirmed recurrent VTE (non fatal or fatal VTE) during the study treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major and clinically relevant non major bleeding</measure>
    <time_frame>during a mean study treatment period of 24 months</time_frame>
    <description>Adjudicated major bleeding (as defined by the criteria of the International Society of Thrombosis and Haemostasis) or clinically relevant non major bleeding during the study treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of recurrent VTE or major bleeding or non major clinically relevant bleeding</measure>
    <time_frame>during a mean study treatment period of 24 months</time_frame>
    <description>The composite of adjudicated recurrent VTE or major bleeding or non major clinically relevant bleeding during the study treatment period will be adjudicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>during a mean study treatment period of 24 months</time_frame>
    <description>Mortality of other cause than recurrent VTE or major or clinically relevant non major bleeding during the study treatment period will be adjudicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>during a mean study treatment period of 24 months</time_frame>
    <description>Treatment compliance will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment effect</measure>
    <time_frame>during a mean study treatment period of 24 months</time_frame>
    <description>The heterogeneity of the treatment effect on predefined strata will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial cardio-vascular events</measure>
    <time_frame>during a mean study treatment period of 24 months</time_frame>
    <description>The arterial cardio-vascular events (myocardial infarction, stroke, cardio-vascular complication other than VTE) will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Reduced dose of DOAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A reduced dose of DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) during a mean follow-up period of 24 months (12 to 48 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full dose of DOAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A full dose of DOAC (Apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily) during a mean follow-up period of 24 months (12 to 48 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced dose of DOAC</intervention_name>
    <description>The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 24 months (12 to 48 months)</description>
    <arm_group_label>Reduced dose of DOAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Full dose of DOAC</intervention_name>
    <description>The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 24 months (12 to 48 months)</description>
    <arm_group_label>Full dose of DOAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;18 years&#xD;
&#xD;
          -  Patients with indications for long-term anticoagulation after VTE (i.e.; symptomatic&#xD;
             PE or proximal DVT) initially treated during 6 (-15 days) to 24 months (+ 3 months) :&#xD;
&#xD;
               -  Patients with multiple episodes of VTE, or&#xD;
&#xD;
               -  Patients with a first episode of unprovoked* VTE&#xD;
&#xD;
               -  Patients with VTE associated with persistent risk factor**, or&#xD;
&#xD;
               -  Patients for whom clinicians feel that indefinite anticoagulation is warranted&#xD;
&#xD;
          -  Social security affiliation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to rivaroxaban and apixaban, allergy to any of the excipients&#xD;
&#xD;
          -  Indication for therapeutic dose anticoagulant therapy&#xD;
&#xD;
          -  Unable or refusal to give informed consent&#xD;
&#xD;
          -  Isolated distal DVT&#xD;
&#xD;
          -  HERDOO2 score ≤ 1&#xD;
&#xD;
          -  Indication for anticoagulation other than DVT or PE (e.g.; atrial fibrillation,&#xD;
             mechanic valves…)&#xD;
&#xD;
          -  Treatment with investigational drug in the past 1 month except for patients benefiting&#xD;
             from an anticoagulant at therapeutic doses for the initial pathology&#xD;
&#xD;
          -  Interruption of anticoagulation for 14 days or more before the inclusion&#xD;
&#xD;
          -  Chronic liver disease or chronic hepatitis&#xD;
&#xD;
          -  Patient considered at high risk of bleeding (eg: previous gastro-intestinal tract&#xD;
             bleeding in the past three months, uncontrolled hypertension, etc.)&#xD;
&#xD;
          -  Renal insufficiency with creatinine &lt;25 ml / min on Cockcroft and Gault formula&#xD;
&#xD;
          -  Antiphospholipid syndrome&#xD;
&#xD;
          -  Dual anti-platelet therapy or aspirin at dosage &gt;100 mg per day&#xD;
&#xD;
          -  Concomitant use of a strong inhibitor of cytochrome P-450 3A4 (CYP3A4) (e.g., a&#xD;
             protease inhibitor for human immunodeficiency virus infection or azole-antimycotics&#xD;
             agents ketoconazole, itraconazole, voriconazole, posaconazole) or a CYP3A4 inducer&#xD;
             (e.g., rifampin, carbamazepine, or phenytoin),&#xD;
&#xD;
          -  Active cancer of less than 6 months&#xD;
&#xD;
          -  Active pregnancy or expected pregnancy&#xD;
&#xD;
          -  No effective contraception in women of childbearing age&#xD;
&#xD;
          -  Life expectancy &lt;12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francis COUTURAUD, PhD</last_name>
    <phone>2 98 34 73 48</phone>
    <phone_ext>+33</phone_ext>
    <email>francis.couturaud@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie BARILLOT</last_name>
    <email>sophie.barillot@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Antoinette SEVESTRE PIETRI, PH</last_name>
      <email>sevestre.marie-antoinette@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie ROY, PUPH</last_name>
      <email>PMRoy@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d'Arras</name>
      <address>
        <city>Arras</city>
        <zip>62022</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandro AQUILANTI, PH</last_name>
      <email>saquilanti@nordnet.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MENEVEAU, PH</last_name>
      <email>nicolas.meneveau@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël CONSTANS, PUPH</last_name>
      <email>joel.constans@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie SKOPINSKI, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA Brest</name>
      <address>
        <city>Brest</city>
        <zip>29240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwénolé ROHEL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis COUTURUAD, PhD</last_name>
      <email>francis.couturaud@chu-brest.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sophie BARILLOT</last_name>
      <email>sophie.barillot@chu-brest.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinique de Clapiers</name>
      <address>
        <city>Castelnau le Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique BRISOT</last_name>
    </contact>
    <investigator>
      <last_name>Dominique BRISOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline DOUTRELON</last_name>
    </contact>
    <investigator>
      <last_name>Caroline DOUTRELON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet médical</name>
      <address>
        <city>Clapiers</city>
        <zip>34830</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Brisot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand - Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannot SCHMIDT, PUPH</last_name>
      <email>jschmidt@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MAHE, PH</last_name>
      <email>isabelle.mahe@lmr.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas FALVO, PH</last_name>
      <email>nicolas.falvo@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital Nord Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles PERNOD, PUPH</last_name>
      <email>Gpernod@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GH Le Havre</name>
      <address>
        <city>Le Havre</city>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bouchra LAMIA</last_name>
      <phone>02 32 73 31 95</phone>
      <email>bouchra.lamia@ch-havre.fr</email>
    </contact>
    <investigator>
      <last_name>Bouchra LAMIA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire NEVEUX</last_name>
      <phone>02 43 43 43 43</phone>
      <email>cneveu@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Claire NEVEUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital de Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe LACROIX, PH</last_name>
      <email>philippe.lacroix@unilim.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29 672</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien BOILEAU</last_name>
      <phone>02 98 62 61 60</phone>
      <email>jboileau@ch-morlaix.fr</email>
    </contact>
    <investigator>
      <last_name>Julien BOILEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane ZUILY, PhD</last_name>
      <email>s.zuily@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre POTTIER, PH</last_name>
      <email>pierre.pottier@univ-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie FERRARI, PUPH</last_name>
      <email>emile.ferrari@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30 029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie RAY</last_name>
      <phone>04 66 68 30 30</phone>
      <email>valerie.RAY@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie RAY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azzedine YAICI, PH</last_name>
      <email>azzedine.yaici@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire LEJEUNNE, PUPH</last_name>
      <email>claire.le-jeunne@htd.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy MEYER, PUPH</last_name>
      <email>guy.meyer@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier SANCHEZ, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Paris Nord Val de Seine</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno CRESTANI, PUPH</last_name>
      <email>bruno.crestani@bch.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MESSAS</last_name>
      <email>emmanuel.messas@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kremlin Bicêtre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flroence PARENT, PH</last_name>
      <email>florence.parent@bct.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Périgueux</name>
      <address>
        <city>Périgueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain MOUKARZEL</last_name>
    </contact>
    <investigator>
      <last_name>Alain MOUKARZEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte PAN-PETESCH, PH</last_name>
      <email>brigitte.pan-petesch@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick JEGO</last_name>
      <email>patrick.jego@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de ROUEN</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ygal BENHAMOU, PH</last_name>
      <email>ygal.benhamou@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Saint Brieuc - Hôpital Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth DUHAMEL, PH</last_name>
      <email>elisabeth.duhamel@ch-stbrieuc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent BERTOLETTI, PUPH</last_name>
      <email>laurent.bertoletti@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick MISMETTI, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Toulon - Hôpital Sainte-Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ELIAS, PUPH</last_name>
      <email>antoine.elias@ch-toulon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Sainte-Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène BARAZZUTTI</last_name>
      <phone>04 83 16 25 13</phone>
      <email>helene.barazzutti@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hélène BARAZZUTTI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Xavier LAPEBIE, PH</last_name>
      <email>lapebie.fx@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Alessandra BURA RIVIERE, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours - Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves Gruel, PUPH</last_name>
      <email>gruel@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Denis ANGOULVANT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59 322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas QUEMENEUR</last_name>
      <phone>03 27 14 30 89</phone>
      <email>quemeneur-t@ch-valenciennes.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas QUEMENEUR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Anticoagulant</keyword>
  <keyword>Direct oral anticoagulant</keyword>
  <keyword>risk of recurrent venous thromboembolism</keyword>
  <keyword>anticoagulant-related bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

